Show simple item record

dc.contributor.authorJové Font, Mariona
dc.contributor.authorPradas Barriga, Irene
dc.contributor.authorNaudí i Farré, Alba
dc.contributor.authorRovira-Llopis, Susana
dc.contributor.authorBañuls, Celia
dc.contributor.authorRocha, Milagros
dc.contributor.authorPortero Otín, Manuel
dc.contributor.authorHernández-Mijares, Antonio
dc.contributor.authorVictor, Victor M.
dc.contributor.authorPamplona Gras, Reinald
dc.date.accessioned2018-02-01T12:00:40Z
dc.date.available2018-02-01T12:00:40Z
dc.date.issued2017
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10459.1/62603
dc.description.abstractPurpose: In this work, a non-targeted approach was used to unravel changes in the plasma lipidome of PCOS patients. The aim is to offer new insights in PCOS patients strictly selected in order to avoid confounding factors such as dyslipemia, obesity, altered glucose/insulin metabolism, cardiovascular disease, or cancer. Results: Multivariate statistics revealed a specific lipidomic signature for PCOS patients without associated pathologies. This signature implies changes, mainly by down-regulation, in glycerolipid, glycerophospholipid and sphingolipid metabolism suggesting an altered biosynthetic pathway of glycerophospholipids and cell signaling as second messengers in women with PCOS. Conclusions: Our study confirms that a lipidomic approach discriminates a specific phenotype from PCOS women without associated pathologies from healthy controls. Methods: In a cross-sectional pilot study, data were obtained from 34 subjects, allocated to one of two groups: a) lean, healthy controls (n = 20), b) PCOS patients (n = 14) with diagnosis based on hyperandrogenaemia, oligo-anovulation and abnormal ovaries with small follicular cysts. A detailed biochemical characterization was made and lipidomic profiling was performed via an untargeted approach using LC-ESI-QTOF MS/MS.ca_ES
dc.description.sponsorshipWe acknowledge funding from the Fund for Health Research (FIS) and co-funding from the European Regional Development Fund of the European Union (FEDER, ‘Una manera de hacer Europa’): PI15/1424, PI16/1083, PI16/0301 and UGP15-193 by FISABIO, to A.H.M, M.R. and V.M.V, respectively. This research was also in part funded by the Spanish Ministry of Economy and Competitiveness, Institute of Health Carlos III (FIS grants PI14/00328), and the Autonomous Government of Catalonia (2017SGR and SLT002/16/00250) to R.P. This study was co-financed by FEDER funds from the European Union (‘Una manera de hacer Europa’).ca_ES
dc.language.isoengca_ES
dc.publisherImpact Journalsca_ES
dc.relation.isformatofReproducció del document publicat a https://doi.org/10.18632/oncotarget.23393ca_ES
dc.relation.ispartofOncotarget, 2017, vol. 9, núm. 4, p. 4522-4536ca_ES
dc.rightscc-by (c) Jové et al., 2017ca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCell signaling moleculesca_ES
dc.subjectGlycerophospholipidsca_ES
dc.subjectFree fatty acidsca_ES
dc.subjectLipidomicsca_ES
dc.titleLipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndromeca_ES
dc.typearticleca_ES
dc.identifier.idgrec027604
dc.type.versionpublishedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.18632/oncotarget.23393


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

cc-by (c) Jové et al., 2017
Except where otherwise noted, this item's license is described as cc-by (c) Jové et al., 2017